Treatment with caspase-1 inhibitor diminishes kidney disease in MRL- <i> Fas <sup>lpr</sup> </i> mice and delays systemic illness
Caspase-1 inhibition effectively ameliorates both systemic and renal manifestations of SLE in MRL-<i>Fas<sup>lpr</sup></i> mice, primarily through suppression of IL-18-mediated inflammation. This study identifies caspase-1 as a promising therapeutic target for SLE and LN, warranting further investigation in clinical trials.
Authors
- Simone Cosima Boedecker-Lips (ORCID: https://orcid.org/0000-0002-7029-2622)
- Paul Claßen (ORCID: https://orcid.org/0000-0002-9410-0525)
- Federica Fasola
- Matthias Plath
- Myriam Meineck (ORCID: https://orcid.org/0000-0002-3243-2540)
- Sabrina Saurin (ORCID: https://orcid.org/0000-0003-0222-2435)
- Andreas Schwarting (ORCID: https://orcid.org/0000-0002-0566-598X)
- Julia Weinmann‐Menke (ORCID: https://orcid.org/0000-0001-7344-8381)
- Andrea Pautz
Institutions
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Acura Kliniken (DE)
Publication Details
- Journal
- RMD Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-006194
- Primary Topic
- Cell death mechanisms and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft